EU approval recommended for Otsuka's Samsca
This article was originally published in Scrip
Executive Summary
The EU's CHMP has adopted a positive opinion for Otsuka's Samsca (tolvaptan), an oral once-daily treatment for hyponatraemia. Samsca was also approved by the US FDA last week (scripnews.com, May 26th, 2008).